Avila Therapeutics, Inc., a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced today that it has relocated to a 23,000 square foot facility located in Bedford, MA. Avila’s new facility in Bedford is more than twice the size of the company’s previous facility in Waltham to accommodate the company’s growth as it advances product candidates derived from its proprietary Avilomics™ covalent drug platform. Avila’s lead product candidate, AVL-292, is a highly specific inhibitor of Bruton’s tyrosine kinase (Btk) and is currently in early clinical development.
“The interest in our pipeline of covalent drugs has intensified remarkably, and we’ve recently expanded our team to advance our product candidates and to support our scientific collaborations,” said Katrine Bosley, Chief Executive Officer of Avila. “We’re delighted to move into this new space and are excited to be a part of the growing biotechnology community in the area.”Cushman & Wakefield represented Avila in leasing the property which is owned, managed and operated by Alexandria Real Estate Equities, Inc.
About Avila Therapeutics™, Inc.
Avila Therapeutics is a clinical-stage biotechnology company focused on the design and development of targeted covalent drugs to achieve best-in class outcomes. The company’s product pipeline has been built using its proprietary Avilomics™ platform and is currently focused on cancer, viral infection and autoimmune disease. Avila’s most advanced product candidate, AVL-292, a potential treatment for cancer and autoimmune diseases, is currently in Phase 1 clinical testing. Avila is funded by leading venture capital firms: Abingworth, Advent Venture Partners, Atlas Venture, Novartis Option Fund, and Polaris Venture Partners.